[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhongshan Hospital (Xiamen), Fudan University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":84},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100639541","phase-1-exploratory-clinical-trial-of-dq1001-in-relapsed-or-refractory-multiple-myeloma-rrmm-100639541",false,"NCT07622862","Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM)","An Early Exploratory Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of DQ1001-a Universal Allogeneic CAR-T Cell Infusion Targeting Both BCMA and GPRC5D-in Patients With Relapsed or Refractory Multiple Myeloma (RRMM).","Inclusion Criteria:\n\n1. Voluntary signing of the Informed Consent Form (ICF) prior to undergoing any study-related procedures.\n2. Age at the time of ICF signing is between 18 and 70 years inclusive.\n3. Diagnosis of relapsed or refractory multiple myeloma (MM), per IMWG criteria:\n\n   * Prior receipt of at least three lines of therapy;\n\n     * Documented progressive disease (PD) during the most recent therapy or within two months after its completion, or documented failure to achieve at least minimal response (MR) within two months after the most recent therapy.\n4. Tumor cells in bone marrow or peripheral blood are BCMA\u002FGPRC5D-positive by flow cytometry; or tumor tissue is BCMA\u002FGPRC5D-positive by immunohistochemistry.\n5. Presence of measurable disease at screening, defined as any one of the following:\n\n   * For IgG-type MM: serum monoclonal M-protein ≥10 g\u002FL; for IgA-, IgD-, IgE-, or IgM-type MM: serum monoclonal M-protein ≥5 g\u002FL; or\n   * Urinary M-protein ≥200 mg\u002F24 h; or\n   * Light-chain MM: involved serum free light chain (FLC) ≥100 mg\u002FL and abnormal serum FLC κ\u002Fλ ratio (\\\u003C0.26 or \\>1.65).\n6. ECOG performance status score of 0-2.\n7. Expected survival ≥12 weeks.\n8. Men with reproductive potential and women of childbearing potential must agree to use effective contraception from the time of ICF signing through two years after the last dose of study drug. Women of childbearing potential include premenopausal women and women within two years of menopause. A negative serum pregnancy test is required at screening for women of childbearing potential.\n9. For patients who previously underwent hematopoietic stem cell transplantation: no active graft-versus-host disease (GVHD), and systemic immunosuppressants discontinued for at least four weeks.\n10. Adequate major organ function, defined as follows:\n\n    * Hematologic: absolute neutrophil count (ANC) ≥1.0 × 10⁹\u002FL; hemoglobin ≥70 g\u002FL; platelet count ≥50 × 10⁹\u002FL; lymphocyte count \\>0.2 × 10⁹\u002FL;\n    * Coagulation: fibrinogen ≥1.0 g\u002FL; activated partial thromboplastin time (APTT) ≤1.5 × upper limit of normal (ULN); prothrombin time (PT) ≤1.5 × ULN;\n    * Hepatic: total bilirubin ≤2 × ULN (≤3 × ULN in patients with Gilbert syndrome); aspartate aminotransferase (AST) ≤3 × ULN; alanine aminotransferase (ALT) ≤3 × ULN;\n    * Cardiopulmonary: left ventricular ejection fraction ≥50%; peripheral capillary oxygen saturation ≥92% without supplemental oxygen, or ≥95% with supplemental oxygen;\n    * Renal: estimated glomerular filtration rate (eGFR) ≥30 mL\u002Fmin\u002F1.73 m² (calculated using the CKD-EPI equation).\n11. Investigator judgment that the participant is able to comply with protocol requirements and complete treatment and follow-up.\n\nExclusion Criteria:\n\n1. Central nervous system (CNS) metastases, leptomeningeal disease, or metastatic CNS compression; or a prior history of CNS disorders, including but not limited to epilepsy, hemiplegia, aphasia, stroke, severe traumatic brain injury, dementia, or Parkinson's disease.\n2. Prior treatment with CAR-T therapy or drugs targeting BCMA or GPRC5D.\n3. Active or moderate-to-severe chronic graft-versus-host disease (GVHD) within four weeks prior to signing the informed consent form (ICF), or systemic GVHD-directed therapy within four weeks before the first infusion.\n4. Any investigational drug or systemic antitumor therapy administered within 28 days (or five half-lives of the drug, whichever is deemed more appropriate by the investigator) prior to the first infusion.\n5. Extensive radiotherapy administered within 28 days prior to signing the ICF; localized palliative radiotherapy to non-target lesions is permitted if administered within 14 days prior to signing the ICF or anticipated during the study period.\n6. Major surgical procedure performed within 28 days prior to signing the ICF, or planned major surgery during the study period.\n7. Positive hepatitis B surface antigen (HBsAg) at screening; or negative HBsAg but positive hepatitis B core antibody (HBcAb) with detectable hepatitis B virus (HBV) DNA in peripheral blood; positive hepatitis C virus (HCV) antibody and HCV RNA; positive human immunodeficiency virus (HIV) antibody; positive cytomegalovirus (CMV) DNA; or positive for both treponemal and non-treponemal antibodies for syphilis.\n8. Known hypersensitivity to any component of the study drugs, including but not limited to lymphodepleting agents (e.g., tocilizumab, cyclophosphamide, fludarabine) or contrast agents used for imaging studies.\n9. Severe respiratory disease (including but not limited to severe or very severe chronic obstructive pulmonary disease, interstitial lung disease); or significant cardiovascular history (including but not limited to coronary artery bypass grafting or percutaneous coronary intervention within six months prior to signing the ICF, myocardial infarction, New York Heart Association \\[NYHA\\] Class III-IV congestive heart failure, unstable angina, corrected QT interval (QTcF) \\> 480 ms, personal or familial history of long or short QT syndrome, uncontrolled severe arrhythmia or hypertension requiring pharmacologic management).\n10. Any comorbidity or other condition judged by the investigator to potentially compromise adherence to the study protocol or render the participant unsuitable for participation in this study.\n11. Pregnant or lactating women, or women planning pregnancy or unwilling to use highly effective, reliable contraception during the study and for two years following completion of study treatment.\n12. Uncontrolled active infection (excluding those viral infections listed above), including but not limited to serious bacterial, fungal, or other viral infections deemed by the investigator to increase the risk associated with study treatment.\n13. Receipt of a live attenuated viral vaccine within one month prior to signing the ICF.\n14. History of immunodeficiency disorder or active autoimmune disease (patients with stable autoimmune disease at enrollment who have not required systemic immunosuppressive therapy for ≥6 months are exempted).\n15. Diagnosis of any malignancy other than multiple myeloma within the past two years prior to screening, except for: malignancies treated with curative intent and without evidence of active disease for ≥2 years prior to enrollment; adequately treated non-melanoma skin cancer with no current evidence of disease; or carcinoma in situ treated with curative intent.","ALL","18 Years","70 Years",{"count":20,"type":21},16,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a prospective, single-arm, open-label, early exploratory clinical study designed to evaluate the safety, tolerability, and efficacy of the DQ1001 cell product in patients with relapsed or refractory multiple myeloma. All participants will receive intravenous infusions of DQ1001. The study consists of two phases: dose escalation and dose expansion. Following identification of an optimal dose during the dose-escalation phase, the cohort receiving that dose will be expanded to include a total of 12 participants-including those enrolled during dose escalation-to further assess the safety, tolerability, and efficacy of DQ1001.",[27,28],"Multiple Myeloma Refractory","Multiple Myeloma Progression","NOT_YET_RECRUITING","2026-05-30",{"date":32,"type":33},"2026-06-03","ACTUAL",{"date":35,"type":21},"2026-06",{"date":37,"type":21},"2028-08",{"name":39,"class":40},"Zhongshan Hospital (Xiamen), Fudan University","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":4},"100637839","phase-2-selinexor-monotherapy-for-cytoreduction-in-bcrabl1-negative-myeloproliferative-neoplasms-100637839","NCT07626021","Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms","An Open-Label, Single-Arm Phase II Study of Selinexor Monotherapy for Cytoreduction in Patients With BCR::ABL1-Negative Myeloproliferative Neoplasms","Inclusion Criteria:\n\n* Aged 18 to 80 years at the time of informed consent.\n* Diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasm, including polycythemia vera, essential thrombocythemia, or primary myelofibrosis, according to World Health Organization criteria.\n* Presence of an indication for cytoreductive therapy, including at least one of the following:\n* Extreme thrombocytosis, defined as platelet count \\>1500 x 10\\^9\u002FL.\n* Progressive leukocytosis, defined as white blood cell count \\>25 x 10\\^9\u002FL.\n* Symptomatic splenomegaly documented by imaging.\n* Severe disease-related symptoms, such as significant weight loss within the past 6 months.\n* Unwillingness or inability to tolerate standard cytoreductive therapies, such as hydroxyurea or interferon.\n* Eastern Cooperative Oncology Group performance status of 0 to 2.\n* Adequate organ function, including renal, hepatic, cardiac, and coagulation function, as determined by laboratory tests and clinical evaluation in the opinion of the investigator.\n* Adequate baseline hematologic function without recent transfusion or growth factor support.\n* Ability to comply with study procedures, visits, and assessments.\n* Ability to understand and willingness to sign a written informed consent form.\n* For women of childbearing potential, a negative pregnancy test before study entry.\n* For participants of reproductive potential, agreement to use effective contraception during the study and for at least 120 days after the last dose of study drug.\n\nExclusion Criteria:\n\n* Diagnosis of Philadelphia chromosome-positive myeloproliferative neoplasm or chronic myeloid leukemia.\n* Concurrent acute leukemia or other active hematologic malignancy.\n* Severe or uncontrolled comorbid condition, including but not limited to significant cardiac or pulmonary disease, decompensated liver disease, or end-stage renal disease.\n* Active uncontrolled bacterial, viral, or fungal infection.\n* Active gastrointestinal disorder associated with significant bleeding or impaired drug absorption.\n* Significant neurologic or psychiatric disorder that may interfere with study participation or compliance.\n* Known hypersensitivity to selinexor or any of its components.\n* Receipt of another investigational agent or participation in another interventional clinical trial within 4 weeks before enrollment.\n* Recent receipt of cytotoxic chemotherapy, radiotherapy, immunotherapy, or other cytoreductive treatment before study entry.\n* History of substance abuse, alcohol dependence, or illicit drug use that may interfere with adherence to study requirements.\n* Another active malignancy requiring systemic treatment.\n* Clinically significant bleeding disorder, severe coagulopathy, or requirement for long-term therapeutic anticoagulation.\n* Receipt of a live vaccine within 30 days before the first dose of study drug, or planned receipt of a live vaccine during the study.\n* Known active infection with human immunodeficiency virus or active viral hepatitis.\n* Estimated life expectancy of less than 12 weeks.\n* Inability to provide informed consent due to cognitive impairment or severe psychiatric illness.\n* Any condition that, in the investigator's judgment, would make the participant unsuitable for participation in this study.","80 Years",{"count":50,"type":21},15,[52],"PHASE2","Myeloproliferative neoplasms are chronic blood cancers in which the bone marrow produces too many blood cells. Patients with Philadelphia chromosome-negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may need treatment to reduce high blood cell counts, relieve disease-related symptoms, and lower the risk of complications. However, currently available cytoreductive treatments may be ineffective, poorly tolerated, or inconvenient for some patients.\n\nSelinexor is an oral selective inhibitor of nuclear export that has shown antitumor activity in several hematologic malignancies. This study will evaluate the effectiveness and safety of selinexor used alone as cytoreductive treatment in patients with Philadelphia chromosome-negative myeloproliferative neoplasms who have an indication for cytoreductive therapy.\n\nThis is a prospective, single-arm, open-label phase II study conducted at a single center. Eligible participants will receive oral selinexor, with dose adjustments based on tolerability and blood cell counts. Participants will be followed for treatment response, symptom improvement, and side effects for up to 6 months. The results of this study may help determine whether selinexor could provide a potential treatment option for patients with Philadelphia chromosome-negative myeloproliferative neoplasms who have limited cytoreductive therapy choices.",[55],"Myeloproliferative Neoplasms","2026-05-29",{"date":58,"type":33},"2026-06-04",{"date":60,"type":21},"2026-07-01",{"date":62,"type":21},"2026-08-31",{"name":39,"class":40},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":71,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},"100638464","phase-2-chidamide-monotherapy-for-intermediate-to-high-risk-myelodysplastic-syndromes-100638464","NCT07616336","Chidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic Syndromes","A Single-Arm, Open-Label Phase II Clinical Trial Evaluating the Efficacy and Safety of Chidamide Monotherapy in Participants With Intermediate-to-High-Risk Myelodysplastic Syndromes","Inclusion Criteria:\n\n* Aged 60 years or older at the time of informed consent.\n* Diagnosis of myelodysplastic syndromes (MDS) according to the World Health Organization (WHO) classification.\n* Intermediate-to-high-risk MDS, defined as at least one of the following:\n* International Prognostic Scoring System (IPSS) risk category of Intermediate-2 or High, with bone marrow blasts \\\u003C15%.\n* Revised International Prognostic Scoring System (IPSS-R) risk category of Intermediate, High, or Very High, with bone marrow blasts \\\u003C15%.\n* Intermediate-1 risk MDS with grade 1 to 3 anemia and not suitable for hypomethylating agent therapy.\n* Evidence of persistent cytopenia affecting one or more hematopoietic lineages for at least 4 months, unless MDS-associated cytogenetic abnormalities or increased blasts are present.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n* Adequate organ function as assessed by laboratory tests within 7 days before enrollment, including liver, renal, and cardiac function, in the opinion of the investigator.\n* Ability to understand and willingness to sign a written informed consent form.\n\nExclusion Criteria:\n\n* Bone marrow blasts \\>=15% at screening.\n* Prior treatment with chidamide.\n* Concurrent diagnosis of acute myeloid leukemia (AML) or other active hematologic malignancy.\n* Receipt of intensive chemotherapy, hypomethylating agents, or other investigational agents within 4 weeks before enrollment.\n* Uncontrolled active infection or severe concurrent medical condition that, in the investigator's judgment, would interfere with study participation.\n* Clinically significant cardiac disease, including uncontrolled arrhythmia or clinically relevant QT interval prolongation.\n* Known hypersensitivity to chidamide or any of its excipients.\n* Participation in another interventional clinical trial at the time of enrollment.\n* Any condition that, in the investigator's judgment, would make the participant unsuitable for participation in this study.","60 Years",{"count":50,"type":21},[52],"Myelodysplastic syndromes (MDS) are a group of bone marrow disorders that can cause low blood cell counts and may progress to acute leukemia. Treatment options for patients with intermediate-to-high-risk MDS are limited, especially for older patients or those who are not suitable for intensive chemotherapy or hypomethylating agents.\n\nChidamide is an oral histone deacetylase inhibitor that has shown antitumor activity in several hematologic malignancies. This study aims to evaluate the effectiveness and safety of chidamide used alone in patients with intermediate-to-high-risk MDS.\n\nThis is a prospective, single-arm, open-label phase II study conducted at a single center. Eligible participants will receive oral chidamide twice weekly and will be followed for treatment response and side effects. The results of this study may help determine whether chidamide could be a potential treatment option for patients with intermediate-to-high-risk MDS who have limited therapeutic choices.",[76],"Myelodysplastic Syndromes",{"date":78,"type":33},"2026-06-01",{"date":60,"type":21},{"date":81,"type":21},"2027-06-30",{"name":39,"class":40},1,""]